Sermorelin: The Complete Guide

Overview

Sermorelin acetate (GRF 1-29 NH₂) is a synthetic peptide consisting of the first 29 amino acids of human growth hormone-releasing hormone (GHRH), which is naturally produced by the hypothalamus. The full endogenous GHRH molecule contains 44 amino acids, but research established that the first 29 residues retain full biological activity for stimulating growth hormone (GH) release from the anterior pituitary gland (Frohman et al., 1992).

Sermorelin was developed as a diagnostic and therapeutic agent and received FDA approval under the brand name Geref (sermorelin acetate for injection). It was approved for evaluating pituitary GH secretory capacity and for the treatment of idiopathic growth hormone deficiency in children with growth failure. Geref represented one of the first clinically available GHRH analogs and established sermorelin as a well-characterized molecule with decades of clinical use (FDA Geref Label).

Unlike exogenous growth hormone (somatropin), which directly replaces GH in the bloodstream, sermorelin works by stimulating the pituitary gland to produce and release GH through the body's own physiological mechanisms. This distinction is clinically significant: sermorelin preserves the natural pulsatile pattern of GH secretion and maintains the hypothalamic-pituitary feedback loop. The pituitary retains the ability to modulate GH output based on the body's needs, which limits the risk of supraphysiological GH levels that can occur with direct GH replacement (Walker, 2006).

Although the branded Geref product has been discontinued by its manufacturer, sermorelin remains widely available through compounding pharmacies. It has become one of the most commonly prescribed peptides in regenerative and anti-aging medicine, used off-label for adult growth hormone insufficiency, body composition optimization, sleep quality improvement, and general recovery support. Its FDA-approved history, long clinical track record, and favorable safety profile distinguish it from many other peptides in current clinical use.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

GHRH Receptor Binding

Sermorelin's mechanism begins at the growth hormone-releasing hormone receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary gland. The GHRH receptor was cloned and characterized in the early 1990s, establishing that GHRH signaling proceeds through the Gsα-adenylyl cyclase-cAMP-PKA pathway (Mayo, 1992).

When sermorelin binds the GHRH-R, it activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels. This triggers protein kinase A (PKA) activation, which leads to:

• GH gene transcription: Increased expression of the GH1 gene in somatotrophs
• GH vesicle exocytosis: Release of preformed GH from secretory granules into the bloodstream
• Somatotroph proliferation: With sustained exposure, GHRH signaling promotes the growth and maintenance of the somatotroph cell population

Preservation of Pulsatile GH Release

Growth hormone is not secreted in a constant stream. Under normal physiology, GH is released in discrete pulses — typically 6–12 pulses per 24 hours, with the largest pulses occurring during slow-wave sleep. This pulsatile pattern is essential for GH's biological effects on tissues; continuous GH exposure produces different (and often less favorable) metabolic outcomes than pulsatile exposure (Frohman et al., 1992).

Sermorelin preserves this pulsatile pattern because it acts upstream of GH itself. The pituitary still responds to:

• Somatostatin (SRIF): The hypothalamic inhibitory hormone that suppresses GH release between pulses. Somatostatin's inhibitory effect is maintained, preventing sustained GH elevation.
• IGF-1 feedback: Rising IGF-1 levels (produced by the liver in response to GH) feed back to suppress both hypothalamic GHRH release and pituitary GH secretion. This negative feedback loop is preserved with sermorelin but bypassed with exogenous GH.
• GH autofeedback: GH itself exerts short-loop negative feedback on the pituitary. This mechanism remains intact with sermorelin.

This preservation of feedback is a key pharmacological distinction between sermorelin and direct GH replacement (somatropin). Exogenous GH administration can suppress endogenous GH production, desensitize GH receptors, and produce supraphysiological GH levels. Sermorelin cannot produce GH levels beyond what the pituitary is capable of secreting — it amplifies the signal but does not override the system's regulatory capacity (Walker, 2006).

Downstream Effects of GH Release

The growth hormone released in response to sermorelin produces its effects through two pathways:

• Direct GH effects: GH binds to GH receptors in muscle, bone, and adipose tissue, promoting lipolysis (fat breakdown), protein synthesis, and cellular repair.
• IGF-1 mediated effects: GH stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic and growth-promoting effects — including collagen synthesis, bone growth, and tissue regeneration.

Why the First 29 Amino Acids Are Sufficient

Endogenous GHRH is a 44-amino-acid peptide (GHRH 1-44). Structure-activity studies demonstrated that the N-terminal 29 residues contain the full pharmacophore — the molecular region responsible for receptor binding and biological activity. Residues 30–44 contribute to peptide stability but are not required for receptor activation. Sermorelin (GHRH 1-29 NH₂) retains full agonist potency at the GHRH-R while being smaller and easier to synthesize (Frohman et al., 1992).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Phase 3 Clinical Trials and FDA Approval

Sermorelin completed the full FDA drug development pathway, including Phase 3 clinical trials, resulting in approval of Geref (sermorelin acetate for injection). The pivotal trials demonstrated that sermorelin effectively stimulated GH release from the pituitary and could be used both diagnostically (to assess pituitary GH reserve) and therapeutically (for GH-deficient children with growth failure). This level of clinical validation — Phase 3 trials, FDA review, and market approval — distinguishes sermorelin from the majority of peptides in current clinical use (FDA Geref Label).

Adult GH Insufficiency and Aging

Growth hormone secretion declines progressively with age — a phenomenon termed "somatopause." By age 60, many adults have GH and IGF-1 levels that are 50–70% lower than young adult values. This decline correlates with increased body fat, decreased lean mass, reduced bone density, impaired sleep quality, and diminished exercise capacity (Corpas et al., 1993).

• Twice-daily GHRH 1-29 in older men: Corpas et al. demonstrated that twice-daily subcutaneous GHRH 1-29 (sermorelin) for 14 days in healthy men aged 60–78 significantly increased 24-hour GH secretion and raised IGF-1 levels toward younger adult ranges. The pulsatile pattern of GH release was preserved (Corpas et al., 1992).
• Single nightly injections in elderly men: Vittone et al. studied nightly subcutaneous GHRH 1-29 injections for 16 weeks in healthy men aged 64–76. Treatment increased nocturnal GH secretion, raised IGF-1 levels, and produced trends toward improved body composition (increased lean mass, decreased fat mass) (Vittone et al., 1997).
• Long-term administration in older adults: Khorram et al. administered a GHRH analog nightly for 6 months to men and women aged 55–71. IGF-1 levels increased significantly. Men showed increased lean body mass (+1.0 kg) and decreased body fat (−2.0 kg). Nitrogen retention improved, suggesting enhanced protein synthesis (Khorram et al., 1997).

Sleep Architecture

Growth hormone secretion is closely linked to slow-wave (deep) sleep. GHRH itself has direct effects on sleep architecture independent of its GH-releasing activity.

• GHRH and slow-wave sleep: Steiger et al. demonstrated that GHRH administration increased slow-wave sleep duration and enhanced nocturnal GH pulses in healthy young men. The sleep-promoting effect appeared to involve a direct hypothalamic mechanism, not merely a secondary consequence of GH release (Steiger et al., 1992).
• Cognitive benefits in older adults: Vitiello et al. found that GHRH administration improved sleep quality and, notably, enhanced cognitive performance (including working memory and processing speed) in healthy older adults. The cognitive improvements correlated with increased slow-wave sleep duration (Vitiello et al., 2006).

Body Composition

Multiple studies have examined the effect of restoring GH secretion via GHRH analogs on body composition in aging adults:

• Lean mass and fat mass: Across multiple trials, GHRH analog administration consistently increased lean body mass and decreased fat mass in older adults. The landmark Rudman et al. study using direct GH replacement demonstrated dramatic body composition changes in men over 60 (increased lean mass, decreased adipose tissue, increased skin thickness). Subsequent studies using GHRH analogs like sermorelin showed similar directional changes with a more physiological approach (Rudman et al., 1990; Khorram et al., 1997).
• Visceral adiposity: Münzer et al. examined GH-axis restoration on regional fat distribution and found reductions in both subcutaneous and visceral abdominal fat with GH-axis stimulation (Münzer et al., 2001).

Diagnostic Use

Sermorelin's original FDA-approved indication included diagnostic testing of pituitary GH secretory capacity. By administering sermorelin and measuring the GH response, clinicians can differentiate between hypothalamic (secondary) and pituitary (primary) causes of GH deficiency. A normal GH response to sermorelin indicates intact pituitary somatotroph function, suggesting the deficiency originates at the hypothalamic level (Rahim et al., 1996; Popovic et al., 2000).

Limitations of the Research

• Most anti-aging studies are small: While sermorelin has FDA approval, the off-label anti-aging research consists of relatively small trials (typically 10–40 subjects per group). Large-scale randomized controlled trials for anti-aging indications have not been conducted.
• Long-term anti-aging outcomes unknown: The effects of long-term (multi-year) sermorelin use on mortality, cardiovascular disease, cancer risk, and other major endpoints have not been studied in controlled trials.
• Surrogate markers vs. clinical outcomes: Many studies report changes in IGF-1 levels, body composition, or sleep metrics — surrogate markers that may or may not translate to meaningful clinical outcomes.
• Population differences: FDA approval was for GH-deficient children and diagnostic use. Extrapolation to otherwise-healthy aging adults represents off-label use with a different risk-benefit calculation.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indications

Source: FDA Geref Prescribing Information

Off-Label Clinical Applications

The following uses are reported in clinical practice by providers specializing in regenerative, anti-aging, and functional medicine. They are based on published research, clinical experience, and the established pharmacology of sermorelin — not on additional FDA-approved indications.

How Sermorelin Differs from Direct GH Replacement

Who Is NOT a Candidate for Sermorelin

• Active malignancy: GH and IGF-1 can promote tumor growth. Sermorelin should not be used in individuals with active cancer without explicit oncologic guidance.
• Pituitary destruction or absence: Sermorelin requires functional pituitary somatotroph cells to work. In patients with pituitary surgery, radiation-induced pituitary damage, or congenital pituitary absence, sermorelin will not produce a GH response.
• Pregnancy and breastfeeding: Safety data in pregnancy is not available.
• Hypersensitivity: Known allergy to sermorelin or any component of the preparation.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

FDA-Approved Dosing (Geref Label)

Source: FDA Geref (sermorelin acetate) Prescribing Information — NDA 020604

Commonly Reported Off-Label Protocols (Adults)

Off-label dosing references: Vittone et al., 1997 · Khorram et al., 1997 · Corpas et al., 1992 · Walker, 2006

Why Bedtime Administration

Sermorelin is typically administered at bedtime for two reasons:

• Physiological timing: The largest natural GH pulses occur during the first 1–2 hours of slow-wave sleep. Bedtime sermorelin augments this natural peak.
• Sleep enhancement: GHRH has direct sleep-promoting effects that benefit from evening administration (Steiger et al., 1992).

Monitoring

Providers typically monitor the following during sermorelin therapy:

• IGF-1 levels: Checked at baseline and every 3–6 months. The goal is typically to restore IGF-1 to the upper-normal range for the patient's age — not to exceed the reference range.
• Fasting glucose and HbA1c: GH can affect insulin sensitivity. Periodic glucose monitoring is standard.
• Symptoms and body composition: Subjective response (sleep quality, energy, recovery) and objective measures (body composition) guide dose adjustments.

Storage

• Lyophilized (unreconstituted) powder: Store refrigerated (2–8°C / 36–46°F). Stable for extended periods when kept dry and cold.
• Reconstituted solution: Refrigerate and use within the timeframe specified by the compounding pharmacy (typically 3–4 weeks). Do not freeze.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What the Evidence Shows

Reported Timeline

Clinical Trial Results

• IGF-1 elevation: Corpas et al. demonstrated significant increases in 24-hour GH secretion and IGF-1 levels within 14 days of twice-daily GHRH 1-29 in older men (Corpas et al., 1992).
• Body composition (6 months): Khorram et al. showed +1.0 kg lean mass and −2.0 kg fat mass in men after 6 months of nightly GHRH analog administration. Nitrogen retention (a marker of protein synthesis) also improved (Khorram et al., 1997).
• Sleep improvement: Steiger et al. documented increased slow-wave sleep duration with GHRH administration in controlled sleep laboratory studies (Steiger et al., 1992).
• Cognitive function: Vitiello et al. reported improved cognitive performance (working memory, processing speed) in healthy older adults receiving GHRH, correlating with sleep quality improvements (Vitiello et al., 2006).

Factors That Influence Response

• Baseline GH/IGF-1 status: Individuals with lower baseline levels tend to show more pronounced improvements. Those with already-normal levels for their age may see minimal change.
• Age: Older adults with greater somatopause-related decline generally show more measurable responses.
• Pituitary function: Sermorelin requires functional pituitary somatotrophs. Individuals with compromised pituitary function (from radiation, surgery, or disease) will have reduced or absent responses.
• Lifestyle factors: Sleep hygiene, exercise, nutrition, and body composition all affect GH axis responsiveness. Sermorelin works synergistically with resistance training and adequate protein intake.
• Consistency: Daily bedtime administration is reported as important for sustained results. Intermittent or inconsistent use produces less reliable outcomes.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Reported Side Effects (from FDA Label and Clinical Use)

Source: FDA Geref Prescribing Information — Adverse Reactions Section

Safety Profile in Context

Sermorelin's safety record spans several decades, encompassing FDA-mandated clinical trials, post-market surveillance, and extensive off-label clinical use. This represents a substantially larger safety dataset than exists for most peptides in current compounding use. No serious systemic toxicity has been attributed to sermorelin at therapeutic doses in the published literature (Walker, 2006).

Several features of sermorelin's mechanism contribute to its safety profile:

• Self-limiting GH elevation: Because sermorelin works through the pituitary (not by directly supplying GH), the GH response is limited by pituitary capacity and modulated by somatostatin feedback. This makes it difficult to achieve dangerously supraphysiological GH levels with sermorelin alone.
• Preserved feedback loops: The hypothalamic-pituitary feedback system remains intact, providing a physiological safety brake against excessive GH/IGF-1 elevation.
• No direct organ toxicity: No organ-specific toxicity has been reported in preclinical or clinical studies at therapeutic doses.

Theoretical Risks and Monitoring Considerations

• GH and cancer: Elevated GH and IGF-1 levels are epidemiologically associated with increased cancer risk (particularly colorectal, breast, and prostate cancers). While sermorelin produces physiological rather than supraphysiological GH levels, providers typically screen for age-appropriate cancer risk before initiating therapy and monitor IGF-1 to avoid exceeding the reference range (Bartke, 2019).
• Insulin resistance: GH antagonizes insulin action. Prolonged GH elevation can impair glucose tolerance. Periodic fasting glucose and HbA1c monitoring is standard practice during sermorelin therapy.
• Fluid retention: GH-mediated sodium and water retention can occur, potentially manifesting as mild edema, carpal tunnel-like symptoms, or joint stiffness. These effects are less common with sermorelin than with direct GH replacement due to the physiological GH levels achieved.
• Antibody formation: The FDA Geref label notes that antibodies to sermorelin developed in some patients during clinical trials. In most cases, these antibodies did not neutralize the GH response, but in rare cases they may reduce efficacy over time.

Drug Interactions

The following are noted in the FDA Geref prescribing information and clinical practice:

• Glucocorticoids: May blunt the GH response to sermorelin. Concurrent use of supraphysiological glucocorticoids can reduce efficacy.
• Insulin and oral hypoglycemics: Monitor glucose closely, as GH can affect insulin sensitivity.
• Thyroid hormones: Hypothyroidism blunts GH response. Thyroid function should be optimized before initiating sermorelin.
• Somatostatin analogs (octreotide): Directly antagonize GHRH signaling. Concurrent use is contraindicated.
• Medications affecting GH response: Atropine, propranolol, and other agents may alter the GH response to sermorelin during diagnostic testing.

Contraindications

• Active malignancy — due to GH/IGF-1 effects on cell proliferation
• Pregnancy and breastfeeding — no adequate safety data
• Known hypersensitivity to sermorelin or any excipient
• Pituitary tumor — theoretical concern for tumor growth

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Approval History

Source: FDA Drug Approval Database — NDA 020604

Why Sermorelin's FDA Status Matters

Sermorelin's FDA-approved history provides several important distinctions compared to peptides that have never been through the FDA approval process:

• Established safety data: Phase 1, 2, and 3 clinical trials were completed with safety monitoring and adverse event reporting. Post-market surveillance data exists.
• Defined pharmacology: The mechanism, pharmacokinetics, and dose-response relationship have been characterized through the regulatory process.
• Compounding legality: As a previously approved molecule, sermorelin occupies a clearer legal position for compounding than substances that have never held FDA approval.
• Provider confidence: The FDA approval history provides a level of pharmacological and safety confidence that does not exist for research-only peptides.

Compounding Pharmacy Access

Sermorelin is currently available through:

• 503A compounding pharmacies: State-licensed pharmacies that prepare patient-specific formulations pursuant to a valid prescription from a licensed provider. Each preparation is made for an individual patient.
• 503B outsourcing facilities: FDA-registered facilities that can produce larger batches of compounded preparations without patient-specific prescriptions, subject to cGMP-adjacent standards and FDA oversight.

A prescription from a licensed healthcare provider is required. Sermorelin is not available over-the-counter or as a dietary supplement.

WADA Prohibited Status

The World Anti-Doping Agency (WADA) lists sermorelin as a prohibited substance under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Specifically, GHRH and its analogs are explicitly named in this section.

• Sermorelin is prohibited at all times (in-competition and out-of-competition) for athletes subject to WADA testing
• Detection methods for GHRH analogs in urine and blood have been developed and are in use
• Athletes should be aware that sermorelin use will result in an anti-doping rule violation regardless of therapeutic intent

DEA / Controlled Substance Status

Sermorelin is not a controlled substance under the U.S. Controlled Substances Act. It is not scheduled by the DEA. It is a prescription medication, but it does not carry the restrictions associated with Schedule II–V substances (such as opioids, benzodiazepines, or testosterone).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

Insurance generally does not cover sermorelin for off-label anti-aging use. Because the branded Geref product is discontinued and off-label compounded preparations are not FDA-approved for the indication being treated, insurance plans do not reimburse for this use. All costs are typically out-of-pocket.

In rare cases where sermorelin is used for a documented GH deficiency diagnosis that matches the original FDA-approved indication, partial coverage may be theoretically possible — but this is uncommon in practice given the availability of FDA-approved somatropin products for GH deficiency.

Cost Comparison: Sermorelin vs. Alternatives

Factors Affecting Cost

• Dose: Higher doses (500 mcg/day) cost more than standard doses (200–300 mcg/day) due to increased product consumption per month.
• Pharmacy: Pricing varies between compounding pharmacies. 503B outsourcing facilities that produce at larger scale may offer lower per-unit pricing.
• Bundled vs. unbundled: Some clinics bundle sermorelin with labs, consultations, and follow-up. Others charge separately for the peptide, provider visits, and blood work.
• Geographic variation: Pricing varies by region and local market competition among anti-aging providers.
• Lab monitoring: IGF-1 and metabolic panels add $50–$200 per draw if not included in a bundled program.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: Sermorelin is the same as HGH.

Answer: Sermorelin and human growth hormone (somatropin/HGH) are fundamentally different molecules with different mechanisms. HGH is a 191-amino-acid protein that directly replaces growth hormone in the bloodstream. Sermorelin is a 29-amino-acid peptide that stimulates the pituitary to release its own GH. This distinction has clinical implications: sermorelin preserves natural pulsatile GH patterns and feedback regulation, while exogenous HGH overrides these mechanisms and can produce supraphysiological levels (Walker, 2006).

Myth: Sermorelin will make you fail a drug test.

Answer: This requires clarification. For workplace drug testing (standard 5-panel, 10-panel, or DOT panels), sermorelin is not tested for and will not cause a positive result. These panels test for drugs of abuse (amphetamines, opioids, THC, etc.), not peptide hormones. For WADA/athletic anti-doping testing, sermorelin is prohibited under Section S2 and can be detected by specialized assays. The distinction between workplace drug screens and athletic anti-doping testing is important.

Myth: Sermorelin stops working after a few months.

Answer: Tachyphylaxis (reduced response over time) has been raised as a theoretical concern with continuous GHRH receptor stimulation. However, clinical studies administering GHRH analogs for 6+ months have shown sustained GH and IGF-1 elevation without evidence of significant tachyphylaxis at therapeutic doses (Khorram et al., 1997). Some providers use intermittent dosing protocols (5 days on, 2 off) as a precautionary measure, though evidence supporting the necessity of this approach is limited.

Myth: Sermorelin is illegal since it's discontinued.

Answer: The discontinuation of the Geref brand was a commercial decision by the manufacturer — not a regulatory action, safety withdrawal, or legal prohibition. Sermorelin remains an FDA-approved molecule (NDA 020604 is on file). It is legally available through licensed compounding pharmacies with a valid prescription from a licensed provider. It is not a controlled substance and is not illegal to prescribe, compound, or possess with a valid prescription (FDA NDA 020604).

Myth: Sermorelin causes cancer.

Answer: This is an oversimplification of a nuanced issue. Elevated GH and IGF-1 levels are epidemiologically associated with modestly increased cancer risk in some population studies. However, sermorelin produces physiological — not supraphysiological — GH levels, and no clinical study or post-market surveillance has identified a direct causal link between therapeutic sermorelin use and cancer development. The appropriate clinical approach is to screen for active malignancy before starting therapy, avoid use in patients with active cancer, and monitor IGF-1 levels to ensure they remain within the reference range (Bartke, 2019).

Myth: You can take sermorelin at any time of day — timing doesn't matter.

Answer: Timing matters. The largest natural GH pulse occurs during early slow-wave sleep. Administering sermorelin at bedtime augments this physiological peak and leverages GHRH's direct sleep-promoting effects. Administration at other times of day may produce a GH pulse that is less aligned with the body's natural rhythm and misses the synergistic sleep benefit. Clinical protocols consistently recommend bedtime administration (Steiger et al., 1992; Vittone et al., 1997).

Myth: Sermorelin is just a placebo — there's no real evidence.

Answer: Sermorelin completed Phase 3 clinical trials and received FDA approval — a process that requires demonstration of efficacy through randomized, controlled studies. Published peer-reviewed trials document measurable increases in GH secretion, IGF-1 levels, lean body mass, and slow-wave sleep duration. While anti-aging outcome trials (long-term mortality, disease prevention) have not been conducted, the claim that there is "no evidence" is factually incorrect (Corpas et al., 1992; Khorram et al., 1997).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Sermorelin is a 29-amino-acid GHRH analog that stimulates the pituitary gland to release growth hormone through natural physiological mechanisms. It preserves the body's pulsatile GH secretion pattern and feedback regulation.
• It is an FDA-approved drug (Geref — NDA 020604), approved for GH deficiency diagnosis and treatment of idiopathic GH deficiency in children. The branded product was voluntarily discontinued by the manufacturer for commercial reasons — not due to safety concerns.
• The evidence base includes Phase 3 trials and decades of clinical use. This distinguishes sermorelin from the majority of peptides currently available through compounding, which lack FDA approval or Phase 3 data.
• Common off-label uses include adult GH insufficiency related to aging, body composition optimization, sleep quality improvement, and recovery support. These uses are based on published clinical trials and provider experience.
• The safety profile is well-characterized and generally favorable. Common side effects are mild: injection site reactions, flushing, headache, and dizziness. Decades of clinical use have not revealed serious systemic toxicity at therapeutic doses.
• Typical dosing is 200–300 mcg subcutaneously at bedtime, aligned with the physiological nocturnal GH surge. Monitoring includes IGF-1 levels and metabolic markers.
• Cost ranges from $99–$400/month through compounding pharmacies. Insurance does not typically cover off-label use. Sermorelin is substantially less expensive than pharmaceutical-grade growth hormone.
• Sermorelin requires a prescription and is available through licensed compounding pharmacies. It is not a controlled substance.

Questions to Ask a Provider

• What are my current IGF-1 and GH levels, and do they suggest a clinical need for GH-axis optimization?
• Is sermorelin appropriate for my situation, or would another approach be more suitable?
• What dosing protocol do you recommend, and what is it based on?
• Which compounding pharmacy do you use, and what quality testing do they perform?
• What monitoring labs will be needed, and how often?
• Are there any interactions with my current medications?
• What results should I realistically expect, and over what timeframe?
• Should I be screened for any conditions (cancer, diabetes) before starting?

Sources & Further Reading

Comprehensive Reviews & Mechanism

• Frohman LA, Downs TR, Chomczynski P (1992) — "Regulation of growth hormone secretion" — Front Neuroendocrinol
• Mayo KE (1992) — "Molecular cloning and expression of a pituitary-specific receptor for GHRH" — Mol Endocrinol
• Walker RF (2006) — "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" — Clin Interv Aging

Clinical Trials & Adult GH Studies

• Corpas E, Harman SM, Piñeyro MA, et al. (1992) — "GHRH 1-29 twice daily reverses decreased GH and IGF-I levels in old men" — J Clin Endocrinol Metab
• Vittone J, Blackman MR, Busby-Whitehead J, et al. (1997) — "Effects of single nightly injections of GHRH 1-29 in healthy elderly men" — Metabolism
• Khorram O, Laughlin GA, Yen SS (1997) — "Endocrine and metabolic effects of long-term GHRH 1-29 in age-advanced men and women" — J Clin Endocrinol Metab
• Merriam GR, Schwartz RS, Vitiello MV (2003) — "GHRH and GH secretagogues in normal aging" — Endocrine

Sleep Architecture

• Steiger A, Guldner J, Hemmeter U, et al. (1992) — "Effects of GHRH and somatostatin on sleep EEG and nocturnal hormone secretion" — Neuroendocrinology
• Vitiello MV, Moe KE, Merriam GR, et al. (2006) — "GHRH improves the cognition of healthy older adults" — Neurobiol Aging

Body Composition

• Rudman D, Feller AG, Nagraj HS, et al. (1990) — "Effects of human growth hormone in men over 60 years old" — N Engl J Med
• Münzer T, Harman SM, Hees P, et al. (2001) — "Effects of GH and/or sex steroid on abdominal fat in healthy aged adults" — J Clin Endocrinol Metab

Diagnostic Use

• Rahim A, Toogood AA, Shalet SM (1996) — "Assessment of GH status using provocative agents" — Clin Endocrinol
• Popovic V, Leal A, Micic D, et al. (2000) — "GHRH and GHRP-6 for diagnostic testing in GH-deficient adults" — Lancet

Aging & GH Axis

• Corpas E, Harman SM, Blackman MR (1993) — "Human growth hormone and human aging" — Endocr Rev
• Bartke A (2019) — "Growth hormone and aging: updated review" — World J Mens Health

Regulatory & FDA Documents

• FDA Geref (sermorelin acetate) Prescribing Information — NDA 020604
• FDA Drug Approval Database — NDA 020604
• FDA: Bulk Drug Substances Used in Compounding
• WADA: Prohibited List

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.